FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      
           
This page is updated frequently with new Cytokine-related patent applications. Subscribe to the Cytokine RSS feed to automatically get the update: related Cytokine RSS feeds. RSS updates for this page: Cytokine RSS RSS


Methods for bilateral renal neuromodulation

Date/App# patent app List of recent Cytokine-related patents
09/25/14
20140288661
 Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal patent thumbnailnew patent Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal
Adult autologous stem cells cultured on a porous, three-dimensional tissue scaffold-implant for bone regeneration by the use of a hyaluronan and/or dexamethasone to accelerate bone healing alone or in combination with recombinant growth factors or transfected osteogenic genes. The scaffold-implant may be machined into a custom-shaped three-dimensional cell culture system for support of cell growth, reservoir for peptides, recombinant growth factors, cytokines and antineoplastic drugs in the presence of a hyaluronan and/or dexamethasone alone or in combination with growth factors or transfected osteogenic genes, to be assembled ex vivo in a tissue incubator for implantation into bone tissue..
09/25/14
20140288545
 Methods for bilateral renal neuromodulation patent thumbnailnew patent Methods for bilateral renal neuromodulation
Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
09/25/14
20140288531
 Methods for bilateral renal neuromodulation patent thumbnailnew patent Methods for bilateral renal neuromodulation
Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
09/25/14
20140286988
 Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom patent thumbnailnew patent Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
1h-imidazo[4,5-c]quinolin-4-amines substituted at the 1-position with a substituent bearing a hydrazinobenzamide or hydrazinonicotinamide, a salt thereof, or a protected hydrazinobenzamide or hydrazinonicotinamide and conjugates made from such compounds are disclosed. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed..
09/25/14
20140286956
 Modulating inflammasome activity and inflammation in the central nervous system patent thumbnailnew patent Modulating inflammasome activity and inflammation in the central nervous system
Compositions and methods for reducing inflammation in the central nervous system (cns) of a mammal that has been subjected to a stroke, traumatic injury to the cns such as traumatic brain injury (tbi), spinal cord injury (sci), or having an autoimmune or cns disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., asc, nalp1) in a mammalian inflammasome (e.g., the nalp1 inflammasome) and have use as treatments for sci, tbi, stroke, and autoimmune and cns diseases in a mammal.
09/18/14
20140275497
 Methods for making cytokine compositions from tissues using non-centrifugal methods patent thumbnailMethods for making cytokine compositions from tissues using non-centrifugal methods
Apparatus and methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The apparatus can include a filter used with a separation system.
09/18/14
20140275279
 Cysteamine in the treatment of fibrotic disease patent thumbnailCysteamine in the treatment of fibrotic disease
Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ecm) deposition, interstitial fibroblasts, interstitial volume, expression of collagen i mrna and protein, expression of profibrotic cytokines and macrophage infiltration by cysteamine treatment..
09/18/14
20140275271
 Novel modified curcumins and their uses patent thumbnailNovel modified curcumins and their uses
Wherein α, β, a, b, and r1-r4 are defined herein. This invention also provides pharmaceutical compositions comprising the above compounds, a method of accelerating the healing of a wound, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (mmp), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting nfκ-b activation in a population of cells..
09/18/14
20140275237
 Beraprost isomer as an agent for the treatment of viral infection patent thumbnailBeraprost isomer as an agent for the treatment of viral infection
In various embodiments the use of single isomer of beraprost as a therapeutic for the treatment of viral disease and other pathologies associated with the induction of a cytokine storm, such as influenza a viruses and the sars-causing coronvirus and mutations thereof is provided.. .
09/18/14
20140274895
 Methods and non-immunogenic compositions for treating inflammatory disorders patent thumbnailMethods and non-immunogenic compositions for treating inflammatory disorders
Methods for making non-immunogenic anti-inflammatory cytokine compositions, comprising (a) obtaining a liquid comprising cytokine producing cells from a mammalian donor; (b) contacting the liquid with a solid extraction material to generate a composition rich in interleukin-1 receptor antagonist; and performing one or both of (i) removing cells from the composition and (ii) freezing the composition. The compositions comprise two or more of il1-ra, stnf-r1, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1rii, compositions may also contain white blood cells and platelets..
09/18/14
20140274894
Methods for making cytokine compositions from tissues using non-centrifugal methods
Non-centrifugal methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The solution rich in il-1ra can also include at least one of stnf-ri, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1 rii..
09/18/14
20140271773
Medical device
The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as cfs compositions), such cfs compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ecs cells), including amnion-derived cellular cytokine solution (referred to herein as accs) obtained from culturing amnion-derived multipotent progenitor (amp) cells, dispersed in a polymeric coating material..
09/18/14
20140271725
Small molecule enhancer for dendritic cell cancer vaccines
Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian dipeptidyl peptidase (dpp) iv activity and/or structural homologues thereof (dash) serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine and/or chemokine production, or (e) stimulating or enhancing production of t-cells, in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian dash serine proteases.
09/18/14
20140271684
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-pd-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer..
09/18/14
20140271652
Immunologically active polypeptide
Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed..
09/18/14
20140271580
Immunoprotective primary mesenchymal stem cells and methods
Immunoprotective primary mesenchymal stems cells (ip-msc) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The ip-msc express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (scfv), fab or f(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., il-2, il-4, il-6, il-7, il-9, and il-12), an interferon (e.g., ifnα, ifnβ, or ifnω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides..
09/18/14
20140271554
Reducing proinflammatory response
The present disclosure provides a method for suppressing a proinflammatory response by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce the levels of proinflammatory cytokines and may be a treatment for inflammatory disease, especially type 1 diabetes.
09/18/14
20140271553
Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising seq id no 4, seq id no 13, seq id no 17, seq id no 21, seq id no 24, seq id no 30, seq id no 31, seq id no 32, seq id no 51, seq id no 57, seq id no 60, and seq id no 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e.
09/18/14
20140271539
Novel use of members of il-10 cytokine family
The invention relates to a novel use of the members of the il-10 cytokine family in wound healing. Particularly, the invention relates to the use of the member of the il-10 cytokine family in the promotion of the proliferation and the migration of keratinocyte cells in wound healing..
09/11/14
20140256682
Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and zoledronic acid.
09/11/14
20140256681
Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and zoledronic acid.
09/11/14
20140255904
Modulating ischemic injury and preserving/storing tissue
The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs.
09/11/14
20140255346
Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis
Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (pbmcs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to cns antigens associated with multiple sclerosis (ms). These cns antigens include, but are not limited to whole brain lysate and the myelin antigens myelin basic protein (mbp), myelin oligodendrocyte glycoprotein (mog), mog peptides (mogps), proteolipid protein (plp), and plp peptides (plpps).
09/04/14
20140249219
Anti-obesity potential of calebin a
The present invention discloses the potential of calebin a in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of calebin a to favorably modulate biochemical markers associated with obesity.
09/04/14
20140249071
Enhanced anabolic cytokine production and delivery system
Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins).
09/04/14
20140248661
Zcytor19 polynucleotides, polypeptides, antibodies and methods of use
Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class ii cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo.
08/28/14
20140242694
Composition containing complex cytokines derived from ebv-infected b cells for inducing the maturation of dendritic cells
A composition for deriving the maturation of dendritic cells includes complex cytokines generated by the simulation, the expression of which is induced on ebv-infected b cells. The dendritic cell maturation process, which conventionally takes approximately 7 days, can be shortened to 2 days, thereby producing dendritic cells in a more economically advantageous and effective manner..
08/28/14
20140242159
Method for preparing a granulate formulation of pirfenidone and pharmaceutically acceptable excipients
A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient.
08/21/14
20140235829
Compositions and methods for regulation of tumor necrosis factor-alpha
The present invention relates to compositions and methods relating to an interleukin 18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (taif) or interleukin-32 (il-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression..
08/21/14
20140234451
Pharmaceutical composition comprising extract of puerariae flos for prevention and treatment of endometriosis
The present invention relates to a pharmaceutical composition containing puerariae flos extracts as active ingredients for preventing or treating endometriosis and the complications thereof. More particularly, puerariae flos extracts exhibit the activity of inhibiting the migration and adhesion of endometriosis cells, inhibiting the expressions of mmp-2 and mmp-9, which are factors associated with migration and adhesion, inhibiting the expression of cox-2, which is a factor associated with pain, and inhibiting the expression of mcp-1, which is a cytokine associated with inflammation, and rantes.
08/21/14
20140234297
Antibody constant domain regions and uses thereof
The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. Dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more fcrs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region..
08/21/14
20140231357
Methods for removing cytokines from blood with surface immobilized polysaccharides
The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.. .
08/21/14
20140230839
Personal care compositions comprising a multi-active system for down regulating cytokines irritation
A personal care composition comprising a multi-active system for down regulating cytokines comprising at least three actives, an extract of camellia sinesis, panthenol, and a glycyrrhizinate salt.. .
08/14/14
20140228427
Pharmaceutical composition containing wogonin as an active ingredient for preventing or treating asthma
The present invention relates to a pharmaceutical composition for the prevention or treatment of asthma comprising wogonin as an active ingredient. The wogonin of the present invention is excellent not only in relieving airway hypersensitivity that causes asthma in vivo, in inhibiting reactive oxygen species generation in the airway, and in inhibiting the infiltration of inflammatory cells in the bronchus, but also in inhibiting the generation of ige in serum and bronchoalveolar lavage fluid, and in inhibiting the expressions of th2 cytokines in the lung.
08/14/14
20140227317
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
Conjugates of an immune response modifier, a linker, and an antigen are disclosed. The linker is represented by formula (i): wherein a is ch or n, p is in a range from 1 to 50, r″ is a bond or -alkylene-o—, r′ is alkylene that is optionally interrupted or terminated with one or more amide or ether groups, and e is an amine- or thiol-reactive group.
08/07/14
20140222163
Artificial dura mater and manufacturing method thereof
Disclosed are an artificial dura mater and manufacturing method thereof. The artificial dura mater includes electrospun layers prepared by electrostatic spinning, at least one of which is a hydrophobic electrospun layer.
08/07/14
20140220675
Platform of dendritic cell (dc)-based vaccination
The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of dc1s generated in serum-supplemented cultures. The invention further discloses methods and systems using ifnγ and other ligands of the ifnγ receptor, in combination with ifnα (or other type i interferons), poly i:c, and other ifnα (and ifnβ) inducers to enhance the il-12-producing properties of dendritic cells.
08/07/14
20140220618
Measuring embryo development and implantation potential with timing and first cytokinesis phenotype parameters
Methods, compositions and kits for determining the developmental potential of one or more embryos are provided. These methods, compositions and kits find use in identifying embryos in vitro that are most useful in treating infertility in humans..
08/07/14
20140220603
Compositions and methods for detecting microbial infections
Provided herein are vaccine compositions for control of trypanosoma cruzi infection and chagas disease. The compositions comprise plasmids encoding o gpi-anchored genes asp-2, tcg-1, tcg2 and tcg4 from trypanosoma cruzi; plasmids encoding cytokines il12 and gm-csf; and plasmids encoding a gene expression system.
08/07/14
20140219920
Immunocytokine combination therapy
Methods and compositions for treating tumours, especially skin tumours, by locally administering single doses of tumour necrosis factor alpha (tnfα) and interleukin-2 (il2) at the tumour site, where the tnfα and il2 are delivered as immunoconjugates comprising an antibody targeted to a splice isoform of an extracellular matrix component such as fibronectin.. .
07/31/14
20140213466
High-throughput assessment method for contact hypersensitivity
The present invention provides methods for high-throughput assessment of in vivo skin sensitizing activity of chemical compounds through detection of secretion levels of cytokine markers implicated in skin sensitization in combination with a multivariate analysis, using support vector machine (svm) for feature selection. The invention includes a computational algorithm that will provide unbiased analysis on the skin cell secretome data and predict the level of skin sensitization.
07/31/14
20140212899
Method for noninvasive prediction or diagnosis of inflammation and infection in amniotic fluid of patients with premature rupture of membranes
Provided is a method for noninvasive prediction or diagnosis of inflammation and/or infection in amniotic fluid leaked through the cervix into the vagina to predict the concentration of inflammatory markers in the amniotic fluid inside uterus by measuring the concentration of inflammatory markers (various cytokines). Further provided is a method for prediction or diagnosis of inflammation and/or infection in amniotic fluid by measuring the concentration of markers (il-6, il-1β il-8, mcp-1, gro-α) in the amniotic fluid leaked through the cervix into the vagina in patients with premature rupture of membranes.
07/31/14
20140212876
Targeting c-rel o-glcnacylation and uses thereof
Serine 350 has been identified as the site of o-glycnacylation of c-rel. Methods are provided for identifying compositions capable of blocking c-rel activation.
07/24/14
20140206758
Expression of il-12 family heterodimers
The present invention provides methods of improving the levels and stability of expression of interleukin-12 family cytokine polypeptides by expressing the alpha and beta subunits of the polypeptides at their determined relative molar ratios that increase the levels and stability of expression of the heterodimer, e.g., in comparison to heterodimer expressed at an equimolar ratio.. .
07/24/14
20140206738
Lipase inhibitors
Is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (i) and determining its lipase inhibitory activity.


Popular terms: [SEARCH]

Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.286

3144

2 - 1 - 71